Business Summary
|
RegeneRx Biopharmaceuticals, Inc. (RegeneRx) is a biopharmaceutical company focused on the discovery and development of molecules to promote tissue and organ repair. As of December 31, 2008, the Company had formulated three product candidates based on Thymosin beta 4 (Tb4), a 43-amino acid peptide, which are in clinical development. RGN-137 is a topically applied gel for hard-to-heal chronic dermal wounds. RGN-259 is a sterile, preservative-free topical eye drop for ophthalmic wounds. RGN-352 is a parenteral or injectable formulation for systemic delivery of Tb4 to treat cardiovascular disease. The Company is initially targeting its parenteral formulation for the treatment of patients with an acute myocardial infarction or heart attack. RegeneRx has a fourth product candidate, RGN-457, in pre-clinical development. RGN-457 is an inhaled formulation of Tb4 targeting cystic fibrosis and other pulmonary diseases.
| | (Source: 10-K)
|
|
|
